SofroniadouSGoldsmithD. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf. 2011;34:97-115.
2.
BordersEBBivonaCMedinaPJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm. 2010;67:2095-106.
3.
EisenTSternbergCNRobertC. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93-113.
4.
LiuAFanningLChongH. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy. 2011;41:1679-1689.
5.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
